GlassScriptPhysician profile
Noa Biran
NPI 1023277910
$263,371.04
in general payments reported to CMS, 2019-2025
27 companies · $44K in 2025
The $44K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $26K · 2021: $32K · 2022: $23K · 2023: $33K · 2024: $48K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Travel and Lodging: $3,130 · Food and Beverage: $2,147 · Honoraria: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,424.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,840.63 |
| Travel and Lodging | $3,130.03 |
| Food and Beverage | $2,146.54 |
| Honoraria | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $58,705.42 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $49,787.24 | 2019-2025 | |
| Pfizer INC. | $32,812.88 | 2021-2025 | |
| Celgene Corporation | $32,443.55 | 2019-2025 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $19,260.61 | 2019-2025 | |
| Amgen INC. | $17,327.92 | 2019-2025 | Kyprolis, Nplate, Xgeva |
| Janssen Scientific Affairs, LLC | $14,975.84 | 2019-2024 | Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $10,266.02 | 2019-2021 | |
| Abbvie INC. | $5,551.37 | 2022-2025 | Venclexta |
| Legend Biotech USA INC. | $5,302.92 | 2024-2025 | Carvykti |
| Janssen Global Services, LLC | $4,433.63 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $3,643.98 | 2025 | Lynozyfic |
| Glaxosmithkline, LLC. | $3,313.01 | 2021-2025 | Blenrep |
| Karyopharm Therapeutics INC. | $2,417.68 | 2020-2024 | Xpovio |
| Sanofi-Aventis U.S. LLC | $2,010.83 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $600.00 | 2022-2023 | Cellsearch |
| Adaptive Biotechnologies Corporation | $299.43 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $80.66 | 2021-2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $59.08 | 2024-2025 | |
| Secura Bio, INC. | $22.58 | 2021 | |
| Ferring Pharmaceuticals INC. | $20.33 | 2023 | Rebyota |
| Pharmaand Gmbh | $18.03 | 2025 | Rubraca |
| Tolmar, INC. | $18.03 | 2025 | Rubraca, Eligard |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noa Biran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.